Fludarabine busulfan conditioning. 14/L): a randomised, non-inferiority, phase 3 trial.
Fludarabine busulfan conditioning. Shah, MD, Dec 7, 2017 · More Intensive Fludarabine/Busulfan (Flu/Bu) Conditioning Regimens Result in Similar Outcomes without Adding Serious Toxicity When Compared to Fludarabine/Melphalan (Flu/Mel) in Patients Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Jeremy Pappacena, PharmD, Valkal Bhatt, PharmD, BCOP, BCPS, Gunjan L. To reduce the risk of recurrence, we evaluated the addition of 400 cGy total body irradiation (TBI) to conditioning with fludarabine-busulfan (Flu/Bu4). The therapeutic window of Bu is well characterized, with strong REFERENCE Sanz J, Boluda JC, Martín C, González M, Ferrá C, Serrano D, de Heredia CD, Barrenetxea C, Martinez AM, Solano C, Sanz MA, Sanz GF. Owing to the high rate of GF with conventional fludarabine (Flu) and busulfan (Bu) RIC, we added low-dose total body irradiation (TBI; 200 cGy) for patients with MF. Methods: We did an open-label, randomised, non-inferiority, phase 3 trial in 31 transplantation centres in France, Germany, Hungary, Italy, and Poland. Interestingly, combinations of busulfan and fludarabine with cladribine, venetoclax, and thiotepa have been shown to synergistically kill leukemia cells in preclinical studies. fludarabine with busulfan (FluBu) and fludar … FluBu4, comprising fludarabine (Flu) combined with a myeloablative dose of intravenous busulfan (Bu; 12. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Dec 1, 2012 · Fludarabine, Busulfan, Antithymocyte Globulin, and Total Body Irradiation for Pretransplantation Conditioning in Acute Lymphoblastic Leukemia: Excellent Outcomes in All but Older Patients with Comorbidities Busulfan plus fludarabine compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with hematologic neoplasms: a meta-analysis In conclusion, the TBF conditioning regimen is an appealing platform in the haplo-HSCT setting with PT-Cy in terms of engraftment rate, toxicity, and disease control. Aug 21, 2021 · Reduced-intensity conditioning (RIC) regimens developed to extend the use of allogeneic hematopoietic stem cell transplantation (HSCT) to older patients have resulted in encouraging outcomes. The use of reduced-toxicity conditioning regimens is an additional approach to providing safe and effective myeloablation. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial Fludarabine (Flu) in combination with 3–4 days standard dose (3. We retrospectively analyzed out … Mar 14, 2022 · Abstract We prospectively studied clofarabine-fludarabine-busulfan (CloFluBu)-conditioning in allogeneic hematopoietic cell therapy (HCT) for lymphoid and myeloid malignancies and hypothesized that CloFluBu provides a less toxic alternative to conventional conditioning regimens, with adequate antileukemic activity. ATG reduced the risk of acute GVHD without comprising outcomes. We retrospectively analyzed 1607 patients aged 50 years or older with acute myeloid leukemia (AML), acute lymphoblastic leukemia, or myelodysplastic syndrom … Read more about the as required review process in this factsheet. In the bu-flu and treo-flu groups, 51. Treosulfan-based conditioning regimens have been found to be equally effective and less toxic. Mar 28, 2025 · To reduce the risk of recurrence, we evaluated the addition of 400 cGy total body irradiation (TBI) to conditioning with fludarabine-busulfan (Flu/Bu4). Nov 2, 2023 · Fludarabine and Melphalan Reduced Toxicity Versus a Myeloablative Fludarabine and Busulfan Conditioning Regimen for Acute Myeloid Leukemia Vikram Mathews, Uday Kulkarni, Sushil Selvarajan, Nov 26, 2023 · Abstract The purine analog fludarabine (Flu) plays a central role in reduced-intensity conditioning and myeloablative reduced-toxicity conditioning regimens because of limited nonhematologic toxicities. 4 mg × Hr/L per day (FluBu4K) and a conventional RIC regimen (FluBu2). We evaluated … The efficacy of thiotepa, busulfan, and fludarabine (TBF) conditioning in lymphoproliferative disorders remains under investigation. Herein we report the outcome of AML and MDS patients conditioned with fludarabine and a myeloablative dose of busulfan (FB4) stratified by age and HCT-CI score. 7% and 99. Shah, MD, Aug 1, 2023 · FBM conditioning (fludarabine, 2 days of busulfan, and melphalan 100 or 140 mg/m2) was associated with a low relapse rate and acceptable nonrelapse mortality (NRM) in patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation. Myeloablative conditioning regimens that contain busulfan plus cyclophosphamide are associated with substantial non-relapse mortality in patients with acute myeloid leukemia (AML) who are undergoing allogeneic hematopoietic cell transplantation (alloHCT). Overall, the use of the myeloablative FluBu4 conditioning with allo-HCT in high-risk multiple myeloma patients resulted in treatment-related mortality rates comparable to those with other fludarabine-based myeloablative regimens. According to the refined Dynamic International Prognostic Scoring System (DIPSS … Jul 1, 2019 · TBF with a myeloablative conditioning (MAC) regimen with busulfan has been compared with busulfan-fludarabine (BF)-MAC in patients with acute myelogenous leukemia (AML) in first remission who underwent transplantation with a matched-sibling donor (MSD) or an MUD. fludarabine with busulfan (FluBu) and fludar … Aug 21, 2021 · Reduced-intensity conditioning (RIC) regimens developed to extend the use of allogeneic hematopoietic stem cell transplantation (HSCT) to older patients have resulted in encouraging outcomes. For MDS patients, one study revealed better RFS after myeloablative conditioning regimens (MAC) 6, whereas the other study suggested slightly better outcomes after RIC 7. The median age was 56 (range 42-70) years. The optimal conditioning regimen for adults undergoing transplantation for acute lymphoblastic leukemia (ALL) remains undetermined. A prospective cohort Nov 15, 2022 · Fludarabine in combination with full dose of busulfan has become the most popular myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with myeloid malignancies, while relapse was till the main obstacle for cure. Fludarabine with busulfan (FB) or melphalan (FM) are 2 more commonly used reduced-intensity conditioning (RIC) regimens for allogeneic stem cell transplantation (HCT). The improved outcomes in patients treated with the treosulfan–fludarabine regimen suggest its potential to become a standard preparative regimen in this population. 8 mg/kg in total), is a widely used conditioning regimen for allo-HSCT, but its usefulness in malignant lymphoma (ML) has not been fully investigated. Jul 8, 2024 · Fludarabine (Flu) in combination with 3–4 days standard dose (3. Dec 2, 2022 · Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell Nov 5, 2024 · Busulfan/Cyclophosphamide (BuCy) and Busulfan/Fludarabine (BuFlu) are both standard myeloablative conditioning (MAC) regimens for adult patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) undergoing allo-HCT. To adapt these principles in the HCT setting, we sought to modify the sequence of busulfan administration in our myeloablative busulfan plus fludarabine (Bu-Flu) conditioning regimen. , Cancer 2015]. While combining busulfan with fludarabine has been proposed as an alternative preparative regimen to reduce non-relapse mortality in these We conducted a registry analysis including adult acute myeloid leukemia (AML) patients in remission who had received thiotepa, busulfan, and fludarabine (TBF) or treosulfan-based (Treo) conditioning for haplo-hematopoietic stem cell transplant Abstract Busulfan (Bu)-containing regimens are commonly used in myeloablative regimens prior to allogeneic hematopoietic cell transplantation (HCT). Yet, there is considerable variability on how Bu is administered related to frequency (four times a day, Q6 or daily, Q24) and the combination with other chemotherapeutic agents (cyclophosphamide, Cy or fludarabine, Flu). Fludarabine has considerable efficacy Nov 5, 2024 · Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation Jan 25, 2019 · TBF with a myeloablative conditioning (MAC) regimen with busulfan has been compared with busulfan-fludarabine (BF)-MAC in patients with acute myelogenous leukemia (AML) in first remission who underwent transplantation with a matched-sibling donor (MSD) or an MUD. Fludarabine plus a reduced dose of busulfan (Flu/Bu2) and intermediate-dose melphalan (140 mg/m 2; Flu/Mel140) are commonly used in RIC regimens for patients with NHL. 2 This study demonstrated treosulfan was associated with a clinical trend towards reduced TRM at 100 days and 1 year after transplant. After a median follow-up of 3 years, satisfactory DC on myeloid and T cells, no graft failures, and a low Nov 25, 2014 · Fludarabine and melphalan provide better acute myeloid leukemia control than fludarabine and busulfan as a reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantatio To investigate the role of antithymocyte globulin (ATG)-containing reduced-intensity conditioning (RIC) in hematopoietic cell transplantation (HCT) from unrelated (UD) or haploidentical family donors (HFD), we conducted a phase 2 trial of 237 patients (age range, 16 to 69 years) with acute myeloid l … A busulfan (Bu) and cyclophosphamide (Cy)–based regimen has been the standard myeloablative chemotherapy, but it is associated with higher treatment-related toxicity, particularly in patients classified as high risk by the Pesaro criteria. Feb 11, 2019 · Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia Nov 15, 2022 · Although reduced-intensity conditioning (RIC) regimens are the standard treatment, the optimal regimen remains unknown. Feb 11, 2019 · Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia The optimal conditioning regimen for elderly patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HCT) remains unclear. To date, no data are available regarding the use of thiotepa, busulfan and fludarabine (TBF) in adult patients allografted for lymphoma. The approach involves intensification of busulfan plus fludarabine treatment followed by addition of combination cladribine plus venetoclax and thiotepa. Feb 1, 2021 · TBF is a feasible conditioning regimen in allo-HCT for MF in all donor settings although longer term outcomes are required. The minimum dose that maintains long‐term donor chimerism is not well established. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT. The dose of busulfan used in this protocol is variable across studies and centers. 8 mg/kg, fludarabine 180 mg/m (2), and melphalan 80 mg/m (2) for single cord blood transplantation (CBT) was conducted at our institution. Dec 17, 2021 · Abstract Adding the selective BCL-2 inhibitor venetoclax to reduced-intensity conditioning chemotherapy (fludarabine and busulfan [FluBu2]) may enhance antileukemic cytotoxicity and thereby reduce the risk of posttransplant relapse. We observed a particularly low incidence of relapse in patients prepared with fludarabine, busulfan and melphalan in our previous study … For acute lymphoblastic leukemia (ALL) patients, total body irradiation (TBI)- based conditioning regimens are the first choice specially in young population. Jun 1, 2025 · A phase II multi-centre randomized controlled study comparing busulfan–fludarabine and treosulfan–fludarabine in non-malignant diseases was published recently. Sep 13, 2024 · Busulfan (Bu) is an important component of many conditioning regimens for allogeneic hematopoietic cell transplantation. We sought to compare the toxicities and outcomes among patients receiving Flu/Bu using either 3 Oct 5, 2023 · In 2010-2020, 251 patients aged <18 years underwent a first matched sibling donor (MSD) HSCT with conditioning based on busulfan-fludarabine (bu-flu; n = 89) or treosulfan-fludarabine (treo-flu; n = 162). We aimed to compare outcomes of the BuFlu regimen with those of the BuCy regimen in HLA-haploidentical hematopoietic cell transplantation (haplo-HCT). A retrospective cohort study was conducted to assess differences in efficacy and tolerability between a busulfan AUC target of 16. The RIC and MAC regimens were dosed at the average daily area under the concentration-vs-time curve (AUC) of 4000 µMol min and 5000-6000 µMol min, or total course AUC of 16,000 µMol min and 20,000-24,000 µMol min Feb 25, 2025 · A clinical trial has evaluated a new regimen as conditioning for allogeneic hematopoietic stem cell transplant (HSCT) in patients with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). We observed a particular low incidence of relapse in patients prepared with double alkylating agents of busulfan and Oct 9, 2019 · Treosulfan was non-inferior to busulfan when used in combination with fludarabine as a conditioning regimen for allogeneic HSCT for older or comorbid patients with acute myeloid leukaemia or myelodysplastic syndrome. Jun 4, 2024 · Reduced-intensity conditioning (RIC) regimens allogeneic hematopoietic stem cell transplantation (HSCT) was developed for older patients or those with poor functional status. compared TBI-Flu versus thiotepa-busulfan-fludarabine (TBF) conditioning for adults with ALL treated with haploidentical (Haplo) allo-HCT [11]. However, several studies have shown an equivalence in clinical outcomes with thiotepa-based conditioning regimen. Promising results were reported for TBF-based conditioning regimens (thiotepa, busulfan, and fludarabine) in patients transplanted from different categories of donors and for various disease types but not speci cally in PT-Cy haplo-SCT for AML. Fludarabine 40 mg/m 2 and intravenous busulfan 130 mg/m 2 were given once daily for 4 days, with tacrolimus-methotrexate as Nov 19, 2010 · Fludarabine, Low Dose Busulfan and Antithymocyte Globulin (ATG) Compared to Fludarabine and Low Dose Total Body Irradiation (TBI) for Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) In Patients with Lymphoid Malignancies. Fludarabine has considerable efficacy in both immunosuppression and tumor cells killing with a minimal extramedullary toxicity. Methods Totally 108 AML-CR1 patients undergoing allo-HSCT were Jan 24, 2025 · Beelen DW, Trenschel R, Stelljes M, et al. We conducted a prospective, randomized, open-label, multicenter study to compare busulfan plus fludarabine (BuFlu) with busulfan plus cyclophosphamide (BuCy) as the conditioning regimen in allogeneic hematopoietic stem cell transplantation Oct 30, 2019 · These results suggest that pretransplantation ruxolitinib, fludarabine/busulfan-based conditioning, and splenic management are keys to improved transplantation outcomes in patients undergoing allo-HCT for MF. Promising results were reported for TBF-based conditioning regimens (thiotepa, busulfan, and fludarabine) in patients transplanted from different categories of donors and for various disease types but not specifically in PT-Cy haplo-SCT for Nov 5, 2024 · Busulfan-based conditioning regimens are efficacious in SCT, though relapse remains a major concern. A randomized study (acronym: MC-FludT. Assess patient pre-transplant using the HCT comorbidity index calculator and the disease risk index assignment tool. The uniform conditioning regimens consisted of fludarabine with pharmacokinetic (PK)-guided intravenous busulfan (Bu). Adult patients with a diagnosis of AML or MDS who received fludarabine + busulfan conditioning with …. Feb 8, 2013 · Abstract Objective: We conducted a prospective, randomized, open-label, multicenter study to compare busulfan plus fludarabine (BuFlu) with busulfan plus cyclophosphamide (BuCy) as the conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute myeloid leukemia (AML) in first complete remission (CR1). Nov 5, 2024 · A recent large registry study reported on the outcomes of busulfan and fludarabine (BuFlu) myeloablative conditioning (MAC) in MF (median age 60 years) showing a 2-year disease free survival (DFS) of 43% with a relapse rate of 41%. Allogeneic reduced intensity conditioning FluBu2 (fludarabine and busulfan) ID: 4003 v. We analyzed outcomes in 157 patients with lymphoid malignancies who underwent a first allogeneic hematopoietic stem cell transplantation (alloHCT) following TBF condit … Jul 8, 2024 · Relapse remains the main cause of treatment failure in patients with myeloid malignancies even after allogeneic hematopoietic stem cell transplantation (allo-HSCT). 7 years. We searched electronic databases from inception through November Key Words: Abstract Fludarabine busulfan anti‐thymocyte globulin is a common conditioning chemotherapy with reduced toxicity used for transplantation in sickle cell disease (SCD). There is evidence to support the use of post-transplant cyclophosphamide (PTCy) for GVHD prophylaxis with this conditioning protocol. We present a systematic review and meta-analysis of studies comparing these 2 RIC regimens. Older age at diagnosis and age-related comorbidities make most patients ineligible for allo-HCT, given concerns for nonrelapse mor … Jun 19, 2023 · The busulfan plus fludarabine (BuFlu) conditioning regimen has lower transplant-related mortality (TRM) than busulfan plus cyclophosphamide (BuCy) in HLA-matched transplantation. Busulfan and cyclophosphamide (BuCy) are currently the most widely used myeloablative regimen to treat malignancies with allogeneic stem cell transplantation. Oct 12, 2022 · More recently, Swoboda et al. Aug 1, 2004 · Postulating favorable antileukemic effect with improved safety, we used intravenous busulfan and fludarabine as conditioning therapy for allogeneic hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). 2 mg/kg/d) of intravenous busulfan (Bu) has become the most popular conditioning regimen in patients with myeloid malignancies, while relapse was the main obstacle for cure [3 - 5]. Among reduced toxicity regimens, the association of busulfan and fludarabine (BuFlu) represents a prototype Allogeneic hematopoietic cell transplantation (allo-HCT) is the only curative treatment modality for primary myelofibrosis (MF) and related myeloproliferative neoplasms. Jul 14, 2020 · Abstract There is a lack of large comparative study on the outcomes of reduced intensity conditioning (RIC) in acute myeloid leukemia (AML) transplantation using fludarabine/busulfan (FB) and fludarabine/melphalan (FM) regimens. Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation Mahshid Mehdizadeh 1, Sayeh Parkhideh 2, Sina Salari Fludarabine with reduced-intensity busulfan (Flu/Bu2) and myeloablative busulfan (Flu/Bu4) are commonly used in conditioning regimens for allogeneic HCT; however, data on their use in patients with NHL is limited. Cyclophosphamide and total body irradiation (Cy/TBI) has emerged as a standard myeloablative regimen but is associated with significant toxicity. To investigate the safety and efficacy of RIC regimen of fludarabine, busulfan, ATG-based haploidentical HSCT in older or unfit patients. We aimed to compare the 2 most commonly used RIC regimens, i. Aug 21, 2024 · These are generally referred to as reduced toxicity myeloablative conditioning regimens. The most common reduced-intensity conditioning (RIC) regimen in both studies was fludarabine plus busulfan. Oct 9, 2019 · We aimed to evaluate the efficacy and safety of conditioning with treosulfan plus fludarabine compared with reduced-intensity busulfan plus fludarabine in this population. 2 Endorsed A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. Nov 15, 2022 · Although reduced-intensity conditioning (RIC) regimens are the standard treatment, the optimal regimen remains unknown. We compared outcomes b … Dec 7, 2017 · More Intensive Fludarabine/Busulfan (Flu/Bu) Conditioning Regimens Result in Similar Outcomes without Adding Serious Toxicity When Compared to Fludarabine/Melphalan (Flu/Mel) in Patients Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Jeremy Pappacena, PharmD, Valkal Bhatt, PharmD, BCOP, BCPS, Gunjan L. We found no benefit of a thiotepa dose of 10 mg/kg compared with a dose of 5 mg/kg. Methods: In this prospective study, 46 patients Our results demonstrate that BU-FLU-MEL is efficacious conditioning for disease control in young patients with myeloid malignancies undergoing MSD or alternative donor allo-HCT, but in the setting of PBSC grafts with cyclosporine A-methotrexate (CSA-MTX) GvHD prophylaxis, it results in an unacceptab … Jun 3, 2024 · The optimal conditioning regimen of ATG-based haplo-HSCT for older or unfit patients remains unknown. Apr 2, 2025 · The efficacy of thiotepa, busulfan, and fludarabine (TBF) conditioning in lymphoproliferative disorders remains under investigation. Jul 12, 2024 · Among currently available regimens, comparative analysis between fludarabine plus busulfan and fludarabine plus melphalan has been a subject in several studies [12, 13]. Nov 10, 2022 · Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison Article 21 February 2024 Jun 6, 2020 · Abstract Purpose Allogeneic hematopoietic stem cell transplantation (HSCT) with optimal conditioning has helped better long-term survival in acute lymphoblastic leukemia (ALL). 4% of patients, respectively, received thiotepa. 2 mg/kg/d) of intravenous busulfan (Bu) has become the most popular conditioning regimen in patients with myeloid malignancies, while relapse was the main obstacle for cure [3, 4, 5]. Nov 5, 2024 · Despite a higher incidence of non-remission transplants, Flu/Bu4/Mel conditioning showed equal or lower relapse rates with a tendency for lower NRM, suggesting it maintains anti-leukemic efficacy while minimizing toxicity. 14/L): a randomised, non-inferiority, phase 3 trial. Feb 21, 2024 · Article Open access Published: 21 February 2024 Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to Nov 2, 2023 · The use of reduced toxicity conditioning regimens allows better disease control with a cost of higher toxicity. Few reports assess the impact of different dose of Flu on the clinical outcomes and the Flu doses vary across reports. v. We performed a retrospectiv … Sep 7, 2021 · Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison Apr 30, 2007 · Busulfan and cyclophosphamide (BuCy) are currently the most widely used myeloablative regimen to treat malignancies with allogeneic stem cell transplantation. We assessed the outcomes associated with thiotepa, busulfan and fludarabine (TBF) conditioning regimen in a cohort of 29 consecutive patients allografted for myelofibrosis (MF). Relapse after haplo-SCT remains a major concern, especially after nonmyeloablative conditioning regimens. Fifty-one patients with myeloid malignancies not in re … Abstract Fludarabine with busulfan (FB) or melphalan (FM) are 2 more commonly used reduced-intensity conditioning (RIC) regimens for allogeneic stem cell transplantation (HCT). Median follow-up was 2. Methods: In this prospective study, 46 patients with myeloid diseases were randomized to Flu/Bu4 or Flu/Bu4/TBI conditioning group. Oct 1, 2025 · In summary, conditioning with melphalan followed by sequential fludarabine and busulfan and consecutive allogeneic stem cell transplantation is an effective treatment option for elderly and comorbid r/r AML patients, especially in patients with low leukemic burden and if a matched stem cell donor is available. 14/L Trial II) demonstrated that fludarabine plus treosulfan (30 g/m²) was an effective and well tolerated conditioning regimen for allogeneic hematopoietic cell transplantation (allo-HCT) in older patients with acute myeloid leukemia (AML) and myelodysplastic s … Dec 1, 2017 · Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan Nov 29, 2018 · Reduced Intensity Conditioning (RIC) Regimens Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML): A Comparison of Fludarabine/Busulfan (FB) and Fludarabine/Melphalan (FM) Based Regimens from the CIBMTR Feb 8, 2013 · Objective We conducted a prospective, randomized, open-label, multicenter study to compare busulfan plus fludarabine (BuFlu) with busulfan plus cyclophosphamide (BuCy) as the conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute myeloid leukemia (AML) in first complete remission (CR1). Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan Nov 13, 2017 · A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis Mar 28, 2025 · Background/Objectives: Allogeneic hematopoietic stem cell transplantation (alloSCT) is a curative treatment for myeloid diseases, yet relapse remains the major cause of post-transplant mortality. Haploidentical donor was appropriate alternative donor for patients without matched donors or patients with emergency disease … Background: Recent studies have shown lower incidences of non-relapse mortality (NRM), acute graft-versus-host disease (aGVHD), and toxicity with Flu/Bu using 2 days of busulfan, whereas Flu/Mel has been associated with longer overall (OS) and relapse-free survival (RFS) [Baron et al. We retrospectively compared alloHCT outcomes in adult patients with MF who received RIC with Flu/Bu/TBI and those who received RIC with Flu/Bu. We aimed to evaluate the efficacy and safety of conditioning with treosulfan plus fludarabine compared with reduced-intensity busulfan plus fludarabine in this population. Similar articles Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies. A pilot study of a novel, reduced-toxicity, myeloablative conditioning regimen using intravenous busulfan 12. Jun 24, 2023 · Bone Marrow Transplantation - Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic We have been using a combination of fludarabine/busulfan plus low-dose total body irradiation (TBI) as the reduced-intensity conditioning (RIC) regimen for patients age ≥ 60 years undergoing allogeneic hematopoietic cell transplantation (HCT) for myeloid malignancies. Targeted busulfan, fludarabine, serotherapy, and HLA-matched hematopoietic stem cell transplantation achieved 100% event-free survival in HLH. This study investigated the efficacy and safety of reduced-intensity conditioning (RIC) with busulfan and fludarabine in adult ALL patients unfit for myeloablation. j4t3lkcupjfc1pvhcw2se74zf9j0oq3pobut